Cong Wang1,2, Qin Yan3, Minmin Hu3, Di Qin3, Zhenqing Feng4. 1. Department of Pathology, Nanjing Medical University, Nanjing, 210029, People's Republic of China. 2. Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China. 3. Department of Microbiology, Nanjing Medical University, Nanjing, 210029, People's Republic of China. 4. Department of Pathology, Nanjing Medical University, Nanjing, 210029, People's Republic of China. fengzhenqing@njmu.edu.cn.
Abstract
BACKGROUND: Ovarian cancer is one of the most common malignant gynecological cancers. Higher expression of AURKA has been found in immortalized human ovarian epithelial cells in previous studies, implying the relationship between AURKA and ovarian cancer pathogenesis. AIM: We investigated the effect of AURKA on angiogenesis and tumorigenesis of human ovarian cancer cells. METHODS: Firstly, the expression of AURKA in HO8910 and SKOV3 ovarian cancer cell lines was knocked down using a vector expressing a short hairpin small interfering RNA (shRNA). Next, the effect of knockdown of AURKA on cell angiogenesis, proliferation, migration, and invasion was determined by microtubule formation assay, proliferation assay, transwell migration, and invasion assays. In addition, the effect of AURKA knockdown on angiogenesis and tumorigenesis was also determined in a chicken chorioallantoic membrane (CAM) model and in nude mice. RESULTS: The results of the microtubule formation assay indicated that knockdown of AURKA significantly inhibited ovarian cancer cell-induced angiogenesis of endothelial cells compared to its control (P < 0.001). Knockdown of AURKA also significantly inhibited cell proliferation, migration, and invasion of HO8910 and SKOV3 cells in vitro. Furthermore, the Matrigel plug assay showed that knockdown of AURKA significantly repressed ovarian cancer cell-induced angiogenesis in nude mice (P < 0.05), and the CAMs model also showed that AURKA knockdown significantly attenuated the angiogenesis (P < 0.001) and tumorigenesis (P < 0.001) of HO8910 cells compared to the control. Finally, the tumorigenicity assay in vivo further indicated that AURKA shRNA reduced tumorigenesis in nude mice inoculated with ovarian cancer cells (P < 0.001). CONCLUSIONS: These results suggest the potential role of AURKA in angiogenesis and tumorigenesis of ovarian cancer, which may provide a potential therapeutic target for the disease.
BACKGROUND:Ovarian cancer is one of the most common malignant gynecological cancers. Higher expression of AURKA has been found in immortalized human ovarian epithelial cells in previous studies, implying the relationship between AURKA and ovarian cancer pathogenesis. AIM: We investigated the effect of AURKA on angiogenesis and tumorigenesis of human ovarian cancer cells. METHODS: Firstly, the expression of AURKA in HO8910 and SKOV3 ovarian cancer cell lines was knocked down using a vector expressing a short hairpin small interfering RNA (shRNA). Next, the effect of knockdown of AURKA on cell angiogenesis, proliferation, migration, and invasion was determined by microtubule formation assay, proliferation assay, transwell migration, and invasion assays. In addition, the effect of AURKA knockdown on angiogenesis and tumorigenesis was also determined in a chicken chorioallantoic membrane (CAM) model and in nude mice. RESULTS: The results of the microtubule formation assay indicated that knockdown of AURKA significantly inhibited ovarian cancer cell-induced angiogenesis of endothelial cells compared to its control (P < 0.001). Knockdown of AURKA also significantly inhibited cell proliferation, migration, and invasion of HO8910 and SKOV3 cells in vitro. Furthermore, the Matrigel plug assay showed that knockdown of AURKA significantly repressed ovarian cancer cell-induced angiogenesis in nude mice (P < 0.05), and the CAMs model also showed that AURKA knockdown significantly attenuated the angiogenesis (P < 0.001) and tumorigenesis (P < 0.001) of HO8910 cells compared to the control. Finally, the tumorigenicity assay in vivo further indicated that AURKA shRNA reduced tumorigenesis in nude mice inoculated with ovarian cancer cells (P < 0.001). CONCLUSIONS: These results suggest the potential role of AURKA in angiogenesis and tumorigenesis of ovarian cancer, which may provide a potential therapeutic target for the disease.
Authors: Tatiana M Gritsko; Domenico Coppola; June E Paciga; Lin Yang; Mei Sun; Sue A Shelley; James V Fiorica; Santo V Nicosia; Jin Q Cheng Journal: Clin Cancer Res Date: 2003-04 Impact factor: 12.531
Authors: M M Tanner; S Grenman; A Koul; O Johannsson; P Meltzer; T Pejovic; A Borg; J J Isola Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: Sangeeta Rojanala; Haiyong Han; Rubén M Muñoz; Walden Browne; Raymond Nagle; Daniel D Von Hoff; David J Bearss Journal: Mol Cancer Ther Date: 2004-04 Impact factor: 6.261
Authors: Gema Moreno-Bueno; Carolina Sánchez-Estévez; Raúl Cassia; Sandra Rodríguez-Perales; Ramón Díaz-Uriarte; Orlando Domínguez; David Hardisson; Miguel Andujar; Jaime Prat; Xavier Matias-Guiu; Juan C Cigudosa; José Palacios Journal: Cancer Res Date: 2003-09-15 Impact factor: 12.701
Authors: Antonio Giovanni Solimando; Matteo Claudio Da Vià; Sebastiano Cicco; Patrizia Leone; Giuseppe Di Lernia; Donato Giannico; Vanessa Desantis; Maria Antonia Frassanito; Arcangelo Morizio; Julia Delgado Tascon; Assunta Melaccio; Ilaria Saltarella; Giuseppe Ranieri; Roberto Ria; Leo Rasche; K Martin Kortüm; Andreas Beilhack; Vito Racanelli; Angelo Vacca; Hermann Einsele Journal: J Clin Med Date: 2019-07-09 Impact factor: 4.241
Authors: Bao-Ai Han; Xiu-Ping Yang; Davood K Hosseini; Po Zhang; Ya Zhang; Jin-Tao Yu; Shan Chen; Fan Zhang; Tao Zhou; Hai-Ying Sun Journal: Sci Rep Date: 2020-06-16 Impact factor: 4.379